174 related articles for article (PubMed ID: 27929666)
41. Functional evaluation of TERT-CLPTM1L genetic variants associated with susceptibility of papillary thyroid carcinoma.
Ge M; Shi M; An C; Yang W; Nie X; Zhang J; Lv Z; Li J; Zhou L; Du Z; Yang M
Sci Rep; 2016 May; 6():26037. PubMed ID: 27185198
[TBL] [Abstract][Full Text] [Related]
42. VDR gene FokI polymorphism as a poor prognostic factor for papillary thyroid cancer.
Beysel S; Eyerci N; Pinarli FA; Apaydin M; Kizilgul M; Caliskan M; Ozcelik O; Kan S; Cakal E
Tumour Biol; 2018 Nov; 40(11):1010428318811766. PubMed ID: 30486759
[TBL] [Abstract][Full Text] [Related]
43. Papillary Thyroid Carcinoma: Association Between Germline DNA Variant Markers and Clinical Parameters.
Jendrzejewski J; Liyanarachchi S; Nagy R; Senter L; Wakely PE; Thomas A; Nabhan F; He H; Li W; Sworczak K; Ringel MD; Kirschner LS; de la Chapelle A
Thyroid; 2016 Sep; 26(9):1276-84. PubMed ID: 27342578
[TBL] [Abstract][Full Text] [Related]
44. Prognostic value of IL-27 polymorphisms and the susceptibility to epithelial ovarian cancer in a Chinese population.
Zhang Z; Zhou B; Wu Y; Gao Q; Zhang K; Song Y; Zhang L; Xi M
Immunogenetics; 2014 Feb; 66(2):85-92. PubMed ID: 24352695
[TBL] [Abstract][Full Text] [Related]
45. The endothelin 1 and endothelin receptor A gene polymorphisms increase the risk of developing papillary thyroid cancer.
Aydin AF; Vural P; Doğru-Abbasoğlu S; Çil E
Mol Biol Rep; 2019 Feb; 46(1):199-205. PubMed ID: 30411193
[TBL] [Abstract][Full Text] [Related]
46. Clinical significance of papillary thyroid cancer risk loci identified by genome-wide association studies.
Wei WJ; Lu ZW; Wang Y; Zhu YX; Wang YL; Ji QH
Cancer Genet; 2015 Mar; 208(3):68-75. PubMed ID: 25746573
[TBL] [Abstract][Full Text] [Related]
47. A functional insertion/deletion polymorphism in the promoter region of the NFKB1 gene increases the risk of papillary thyroid carcinoma.
Wang X; Peng H; Liang Y; Sun R; Wei T; Li Z; Gong Y; Gong R; Liu F; Zhang L; Zhu J
Genet Test Mol Biomarkers; 2015 Mar; 19(3):167-71. PubMed ID: 25692306
[TBL] [Abstract][Full Text] [Related]
48. IL-27 -964A>G polymorphism and the risk of breast cancer: a case-control study.
Zhang S; Wang Y; Wang M; Ji Z
Tumour Biol; 2014 Dec; 35(12):12099-102. PubMed ID: 25146683
[TBL] [Abstract][Full Text] [Related]
49. Interleukin-1 beta polymorphisms are associated with lymph node metastasis in Korean patients with papillary thyroid carcinoma.
Ban JY; Kim MK; Park SW; Kwon KH
Immunol Invest; 2012; 41(8):888-905. PubMed ID: 23215728
[TBL] [Abstract][Full Text] [Related]
50. Association Between Genetic Polymorphisms in the Promoter Regions of Let-7 and Risk of Papillary Thyroid Carcinoma: A Case-Control Study.
Wang Y; Wei T; Xiong J; Chen P; Wang X; Zhang L; Gao L; Zhu J
Medicine (Baltimore); 2015 Oct; 94(43):e1879. PubMed ID: 26512603
[TBL] [Abstract][Full Text] [Related]
51. Polymorphisms at the IL17A and IL17RA Genes are Associated with Prognosis of Papillary Thyroid Carcinoma.
Bertol BC; Góes de Araújo JN; de Carvalho KTC; Gonzaga Dos Santos M; Martelli-Palomino G; de Figueiredo Feitosa NL; Maciel LMZ; Silbiger VN; Lucena-Silva N; Freitas JCOC; Donadi EA
Arch Med Res; 2022 Feb; 53(2):163-169. PubMed ID: 34384609
[TBL] [Abstract][Full Text] [Related]
52. Association of
Chatzikyriakidou A; Chorti A; Papavramidis T
In Vivo; 2019; 33(6):2281-2285. PubMed ID: 31662568
[TBL] [Abstract][Full Text] [Related]
53. Common genetic variants related to genomic integrity and risk of papillary thyroid cancer.
Neta G; Brenner AV; Sturgis EM; Pfeiffer RM; Hutchinson AA; Aschebrook-Kilfoy B; Yeager M; Xu L; Wheeler W; Abend M; Ron E; Tucker MA; Chanock SJ; Sigurdson AJ
Carcinogenesis; 2011 Aug; 32(8):1231-7. PubMed ID: 21642358
[TBL] [Abstract][Full Text] [Related]
54. [Association of genetic polymorphisms and haplotypes in hMLH1 and hMSH3 gene with the risk of papillary thyroid carcinoma].
Shi WP; Bian JC; Jiang F; Ni HX; Zhu QX; Tang HW; Shen Q; Wu Y
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Aug; 25(4):390-5. PubMed ID: 18683134
[TBL] [Abstract][Full Text] [Related]
55. A cyclin D1 (CCND1) gene polymorphism contributes to susceptibility to papillary thyroid cancer in the Turkish population.
Aytekin T; Aytekin A; Maralcan G; Gokalp MA; Ozen D; Borazan E; Yilmaz L
Asian Pac J Cancer Prev; 2014; 15(17):7181-5. PubMed ID: 25227811
[TBL] [Abstract][Full Text] [Related]
56. Single nucleotide polymorphisms of ataxia telangiectasia mutated and the risk of papillary thyroid carcinoma.
Song CM; Kwon TK; Park BL; Ji YB; Tae K
Environ Mol Mutagen; 2015 Jan; 56(1):70-6. PubMed ID: 25196645
[TBL] [Abstract][Full Text] [Related]
57. Association of the ATM gene polymorphisms with papillary thyroid cancer.
Gu Y; Yu Y; Ai L; Shi J; Liu X; Sun H; Liu Y
Endocrine; 2014 Apr; 45(3):454-61. PubMed ID: 23925578
[TBL] [Abstract][Full Text] [Related]
58. Cumulative risk impact of five genetic variants associated with papillary thyroid carcinoma.
Liyanarachchi S; Wojcicka A; Li W; Czetwertynska M; Stachlewska E; Nagy R; Hoag K; Wen B; Ploski R; Ringel MD; Kozłowicz-Gudzinska I; Gierlikowski W; Jazdzewski K; He H; de la Chapelle A
Thyroid; 2013 Dec; 23(12):1532-40. PubMed ID: 23659773
[TBL] [Abstract][Full Text] [Related]
59. Diffuse sclerosing variant of papillary thyroid carcinoma: major genetic alterations and prognostic implications.
Joung JY; Kim TH; Jeong DJ; Park SM; Cho YY; Jang HW; Jung YY; Oh YL; Yim HS; Kim YL; Chung JH; Ki CS; Kim SW
Histopathology; 2016 Jul; 69(1):45-53. PubMed ID: 26568156
[TBL] [Abstract][Full Text] [Related]
60. Association between CTLA-4 + 49A > G and - 318C > T single-nucleotide polymorphisms and susceptibility to thyroid neoplasm.
Abtahi S; Izadi Jahromi F; Dabbaghmanesh MH; Malekzadeh M; Ghaderi A
Endocrine; 2018 Oct; 62(1):159-165. PubMed ID: 30078171
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
